Navigation Links
Digestive Care, Inc. Announces the Complete Submission of the NDA for PANCRECARB(R) (pancrelipase)
Date:10/27/2008

BETHLEHEM, Pa., Oct. 27 /PRNewswire/ -- Digestive Care, Inc. (DCI) announced today that it has completed the submission of the New Drug Application ("NDA") for PANCRECARB(R) (pancrelipase), used in the treatment of Exocrine Pancreatic Insufficiency ("EPI"), to the U.S. Food and Drug Administration ("FDA"). The FDA had previously granted the product Fast Track designation and approved a rolling NDA submission schedule.

"Digestive Care has provided vital products used to improve the nutritional status of patients living with chronic diseases, such as cystic fibrosis, for over a decade. We are excited about the results of our Clinical Trials submitted with the PANCRECARB(R) NDA, and are pleased to have completed the NDA submission prior to the April 28, 2009 deadline set forth by the FDA," said Dr. Tibor Sipos, President and Chief Scientific Officer. "PANCRECARB(R) is a unique bicarbonate buffered enteric-coated formulation of pancrelipase that has been an essential component of the armamentarium for the treatment of EPI associated with cystic fibrosis (CF) and other diseases affecting the pancreas. We are dedicated to continuing to provide PANCRECARB(R) to CF patients and others suffering from EPI," added Dr. Sipos.

The results of the recently completed randomized, double-blind, placebo-controlled, multi-center, crossover study on PANCRECARB(R) MS-16 was presented at the 2008 North American Cystic Fibrosis Conference, October 23-25 in Orlando, Florida.

About PANCRECARB(R)

PANCRECARB(R) is a pancreatic enzyme replacement therapy for the treatment of Exocrine Pancreatic Insufficiency. It is the only enteric coated, bicarbonate buffered pancreatic enzyme available on the market today, and several U.S. patents protect PANCRECARB(R). In April 2004, the FDA determined that prescription exocrine pancreatic insufficiency drug products are medically necessary and, accordingly, allowed the drug manufacturers four years (April 2008) to obtain approved new drug applications. The FDA then announced the deadline extension for unapproved pancreatic enzyme drug products to April 28, 2010, but only if the manufacturers have investigational new drug applications on active status on or before April 28, 2008 and have submitted NDAs on or before April 28, 2009.

About Digestive Care, Inc.

DCI is a privately held fully integrated pharmaceutical company dedicated to developing unique pharmaceutical products to alleviate complications and symptoms of gastrointestinal disorders. DCI was founded in 1990. The company holds 15 U.S. and foreign patents and has a national distribution network. The technology of DCI is based on the ability to commercially develop unique drug delivery systems for delivering bioactive molecules to their target site. The company has grown from an initial research based organization to a fully integrated pharmaceutical company encompassing Research, Product Development, Manufacturing, Packaging, Distribution, Marketing, and Sales. DCI's research into the controlled delivery of gastric acid resistant digestive enzymes and buffered bile acids through micro encapsulation led to the development of the successful drug product, PANCRECARB(R) (pancrelipase) which is manufactured in the USA. For information, please visit us at http://www.digestivecare.com.


'/>"/>
SOURCE Digestive Care, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. MyHealthGate, Inc. Joins With LiveActive Chewy Granola Bars to Raise Digestive Health Awareness
2. 2009 Half Marathon Training Program to Benefit Research into Debilitating Digestive Diseases
3. Obesity raises risks of serious digestive health concerns
4. String probes for devastating childhood digestive disease
5. Digestive Disease Week study examined ACRs guidelines for CT colonography interpretation
6. Digestive Care, Inc. Announces the Filing of the First Module of NDA Submission for PANCRECARB(R) (pancrelipase)
7. North South Divide Exists in UK Digestive Health
8. New Friendship Cottage Cheese Boosts Digestive & Bone Health
9. TAK-390MR Phase 3 data presented at Digestive Disease Week
10. Mayo Clinic Proceedings examines link between bacteria in the digestive system and obesity
11. Mayo Clinic Proceedings Examines a Possible Link Between Bacteria Found in the Human Digestive System and Obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... 2016 , ... The Association of Home Care Coding & ... Health and Hospice ICD-10 Transition Workgroup are working closely with the American Hospital ... to address concerns over the use of 'A' as the seventh character indicating ...
(Date:2/8/2016)... ... 08, 2016 , ... Joshua Rosenthal, PhD, Chief Scientific Officer ... use newly released government data on populations and physicians to better calculate risk ... the value they create to succeed in new economic models for value based ...
(Date:2/8/2016)... ... , ... The schedule is now online for the largest and ... is being held May 25-29 at the Loews Chicago O’Hare Hotel, continues to give ... of chronic illness in children. , Very recent articles have cited 1 child in ...
(Date:2/7/2016)... Birmingham, Lake Orion, Clarkston, Metamora, Michigan (PRWEB) , ... ... ... the ability to correct pelvic organ prolapse with the latest techniques and the ... at greatest risk for pelvic organ prolapse, particularly after menopause. Other risk factors ...
(Date:2/7/2016)... ... February 07, 2016 , ... HealthSmart Holdings, Inc. announced today ... the tools and information to lower the costs, and increase the impact of ... providing employee healthcare benefits by as much as 22%:, + Price and ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... Calif. , Feb. 8, 2016  HemaFlo Therapeutics, Inc. ... (USPTO) has issued US Patent Number 9,119,880 covering the use ... Dale Peterson , PhD, HemaFlo,s founder, said, "We are ... --> Dale Peterson , PhD, HemaFlo,s founder, ... a powerful technology." --> Dale Peterson ...
(Date:2/8/2016)... Pharma Inc. President and Chief Executive Officer Yoshihiko Hatanaka ... as president, Americas Operations, for Astellas US LLC, with responsibility ... America , effective April 1, 2016.  Robinson previously served ... the United States -- a role ... who is retiring in June 2016.  --> ...
(Date:2/8/2016)... 8, 2016 --> ... by Allied Market Research titled, "World Synthetic ... 2014-2020", estimates the world synthetic biology market to ... sequencing technology segment would continue to lead the ... segment, collectively, held around half of the market ...
Breaking Medicine Technology: